Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246194 · ClinicalTrials.gov registry record
Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)
A clinical trial, sponsored by Janssen.
- Completed
- Registry status
- 532
- Enrollment target
NCT00246194 is a clinical trial that has completed, run by Janssen. The registered enrollment target is 532 participants.
The verdict
NCT00246194 has completed, sponsored by Janssen.
- COMPLETED
- Registry status
- 532 participants
- Enrollment target
Study Summary
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.
Interventions
- DRUG risperidone (RISPERDAL CONSTA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246194
The ClinicalTrials.gov registry entry for NCT00246194 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone (RISPERDAL CONSTA) is the first listed.
NCT00246194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246194 about?
NCT00246194 is a clinical study titled "Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)". The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.
What is the current status of trial NCT00246194?
This trial is currently completed. The enrollment target is 532 participants. The study started on 2004-09. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00246194?
The interventions under investigation include: risperidone (RISPERDAL CONSTA) (DRUG).
Who is sponsoring clinical trial NCT00246194?
This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.